search
Back to results

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? (RIPCORD 2)

Primary Purpose

Chest Pain, Stable Angina, Acute Coronary Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Routine Measurement of FFR
Sponsored by
University Hospital Southampton NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Chest Pain focused on measuring Fractional flow reserve (FFR), Pressure wire (PW), Coronary angiography

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

· Inclusion criteria

o Outline Initial Inclusion Criteria (before entry to cath lab):

Patient scheduled for coronary angiography for the:

  • Elective investigation of known or suspected coronary artery disease OR
  • Urgent investigation of a recent but stabilised, non-ST elevation acute coronary syndrome event

    o Outline Angiographic Inclusion Criterion (after angiography):

  • Presence of significant coronary disease defined as:

Any stenosis >30% reduction in luminal diameter, by visual estimate, in at least one vessel (main or branch) of sufficient calibre to permit the potential performance of PCI - approximately 2.25 mm diameter.

  • Key Exclusion Criteria

    • Screening phase exclusion criteria:

      • ≤ 18 years of age
      • Previous enrolment in this trial
      • Currently enrolled into another study unless co-enrolment approved by Chief Investigator (CI) and the clinical trials unit (CTU)
      • Inability to provide informed consent
      • Residence outside the United Kingdom (UK) or other issues limiting the ability to secure clinical follow-up data to one year
      • Non-cardiac pathology that may limit survival in the next year
      • Clear contraindication to potential future management with CABG or PCI (patients should be a potential candidate for medical therapy or revascularisation with either PCI or surgery)
      • Heart valve disease of sufficient import to consider valve replacement or other intervention as part of an index management strategy
      • Hypertrophic cardiomyopathy
      • Previous coronary artery surgery of any type
      • Known chronic renal impairment with a current estimated glomerular filtration rate (eGFR) of < 45
      • Anaemia with a current measured haemoglobin of < 100
      • Angiography performed in the context of an ST elevation myocardial infarction event
      • Any patient who at the time of planned angiography manifests haemodynamic instability, or recurrent sustained ventricular arrhythmia, or Mobitz type II or complete heart block
      • Any patient who at the time of planned angiography manifests unstable chest pain symptoms at rest or has required the continuing use of intravenous nitrates or regular opioid analgesia to control symptoms
      • Continuing use of intravenous glycoprotein 2b/3a (GP2b3a) agents before entry to the catheterisation laboratory
      • Known intolerance, hypersensitivity or contraindication to adenosine - including significant reversible airways disease
      • Additional investigations planned (or deemed likely to be required) for the assessment of myocardial ischaemia or viability. Examples of proposed tests that would constitute an exclusion criterion would include, but are not limited to, exercise tolerance testing, stress echocardiography, cardiac MRI viability or perfusion scanning or nuclear myocardial perfusion scanning.
      • Active bleeding at the time of planned index angiography
      • Pregnant women
    • Angiographic phase exclusion criteria:

      • Single vessel occlusive coronary disease (TIMI flow <3) as sole disease
      • Patient not suitable for the immediate performance of a pressure wire assessment of all major vessels for any reason, for example:

        • Patient discomfort
        • Change in the clinical condition or complication of angiography requiring termination of the procedure or immediate intervention
        • Significant use of radiographic contrast or X-Ray exposure during the initial angiography
        • Inadequate angiographic images or failure to intubate any of the coronary vessels
        • Aorto-ostial disease that would preclude accurate assessment of FFR
        • Insufficient laboratory time
        • Uncertain availability of key clinical and trial staff
        • PW use in coronaries declared unsafe (e.g. tight or long disease)
        • PW use in coronaries declared unsuitable (e.g. distal disease or complete cross-filling)

Sites / Locations

  • Royal Bournemouth Hospital - The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
  • Brighton and Sussex University Hospitals NHS Trust
  • Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust
  • Southampton General Hospital - University Hospitals Southampton NHS Foundation Trust
  • Royal Blackburn Teaching Hospital - East Lancashire Hospitals NHS Trust
  • Liverpool Heart and Chest Hospital NHS Foundation Trust
  • Freeman Hospital - Newcastle Hospitals
  • King's Mill Hospital - Sherwood Forest Hospitals NHS Foundation Trust
  • City Hospital - Nottingham University Hospitals NHS Trust
  • Golden Jubilee National Hospital
  • Northern General Hospital - Sheffield Teaching Hospitals
  • Royal Stoke University Hospital - University Hospitals of North Midlands
  • Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust
  • Pinderfields Hospital - The Mid Yorkshire Hospitals NHS Trust
  • Castle Hill Hospital - Hull and East Yorkshire Hospitals NHS Trust
  • Leeds General Infirmary - Leeds Teaching Hospitals NHS Trust
  • Bristol Heart Institute - University Hospitals Bristol NHS Foundation Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Conventional angiography

Routine Measurement of FFR

Arm Description

Routine angiography will be performed according to local best practice

Additional investigation with the measurement of FFR in all major vessels

Outcomes

Primary Outcome Measures

Primary Economic Outcome Measure
Resource utilisation as determined by hospital care costs at one year; All hospital admissions will be tracked using national hospital episode statistics; the cost of each episode will be derived from a cost model using standard UK tariffs. This analysis will compare the mean (or median) of the total hospital costs recorded for each patient over the 12 month follow-up period.
Primary Quality of Life Outcome Measure
Patient reported quality of life at one year using the EQ-5D health questionnaire.

Secondary Outcome Measures

Management strategy information
· Proportion of vessels deemed to demonstrate flow-limiting disease and targeted for revascularisation in the declared initial management strategy.
Management strategy information
· Proportion of patients scheduled for management with medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in the declared initial management strategy.
Angina symptoms
• Angina symptoms as reported by the research team after the 12 month contact, described by Canadian Cardiovascular Society Grade.
Angina symptoms
• Angina symptoms as reported by the patient with private completion of a screening form at 12 months, described by Canadian Cardiovascular Society Grade.
All-cause mortality
Number of hospitalisation events
Total hospital days
Hospitalisation events
Hospitalisation events coded as cerebro-vascular accident (CVA).
Hospitalisation events
Hospitalisation events coded as myocardial infarction.
Hospitalisation events
Hospitalisation events coded as Coronary revascularisation. This analysis will involve a pre-specified subgroup analysis of: Planned revascularisation - if declared as the index strategy. All additional revascularisation events.

Full Information

First Posted
July 6, 2016
Last Updated
August 8, 2019
Sponsor
University Hospital Southampton NHS Foundation Trust
Collaborators
Liverpool Heart and Chest Hospital NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT02892903
Brief Title
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
Acronym
RIPCORD 2
Official Title
A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Unknown status
Study Start Date
September 2016 (undefined)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
March 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital Southampton NHS Foundation Trust
Collaborators
Liverpool Heart and Chest Hospital NHS Foundation Trust

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomised controlled trial to compare two strategies for the investigation of coronary artery disease at the time of angiography. Patients will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm).
Detailed Description
The study will recruit patients undergoing angiography for the investigation of stable angina or for the assessment of a recent, but stabilised, non-ST elevation acute coronary syndrome event. Eligible patients who provide written informed consent will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm). The study pragmatic design allows investigators to conduct all diagnostic and therapeutic management in accordance with prevailing best practice patterns. Study outcome measures will examine resource utilisation, patient reported quality of life and clinical events at 1 year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chest Pain, Stable Angina, Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Keywords
Fractional flow reserve (FFR), Pressure wire (PW), Coronary angiography

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Conventional angiography
Arm Type
No Intervention
Arm Description
Routine angiography will be performed according to local best practice
Arm Title
Routine Measurement of FFR
Arm Type
Experimental
Arm Description
Additional investigation with the measurement of FFR in all major vessels
Intervention Type
Device
Intervention Name(s)
Routine Measurement of FFR
Other Intervention Name(s)
Pressure wire assessment
Intervention Description
FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
Primary Outcome Measure Information:
Title
Primary Economic Outcome Measure
Description
Resource utilisation as determined by hospital care costs at one year; All hospital admissions will be tracked using national hospital episode statistics; the cost of each episode will be derived from a cost model using standard UK tariffs. This analysis will compare the mean (or median) of the total hospital costs recorded for each patient over the 12 month follow-up period.
Time Frame
One year
Title
Primary Quality of Life Outcome Measure
Description
Patient reported quality of life at one year using the EQ-5D health questionnaire.
Time Frame
One year
Secondary Outcome Measure Information:
Title
Management strategy information
Description
· Proportion of vessels deemed to demonstrate flow-limiting disease and targeted for revascularisation in the declared initial management strategy.
Time Frame
Reported once: Single declaration at index procedure after randomisation
Title
Management strategy information
Description
· Proportion of patients scheduled for management with medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in the declared initial management strategy.
Time Frame
Reported once: Single declaration at index procedure after randomisation
Title
Angina symptoms
Description
• Angina symptoms as reported by the research team after the 12 month contact, described by Canadian Cardiovascular Society Grade.
Time Frame
One year
Title
Angina symptoms
Description
• Angina symptoms as reported by the patient with private completion of a screening form at 12 months, described by Canadian Cardiovascular Society Grade.
Time Frame
One year
Title
All-cause mortality
Time Frame
One year
Title
Number of hospitalisation events
Time Frame
One year
Title
Total hospital days
Time Frame
One year
Title
Hospitalisation events
Description
Hospitalisation events coded as cerebro-vascular accident (CVA).
Time Frame
One year
Title
Hospitalisation events
Description
Hospitalisation events coded as myocardial infarction.
Time Frame
One year
Title
Hospitalisation events
Description
Hospitalisation events coded as Coronary revascularisation. This analysis will involve a pre-specified subgroup analysis of: Planned revascularisation - if declared as the index strategy. All additional revascularisation events.
Time Frame
One year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
· Inclusion criteria o Outline Initial Inclusion Criteria (before entry to cath lab): Patient scheduled for coronary angiography for the: Elective investigation of known or suspected coronary artery disease OR Urgent investigation of a recent but stabilised, non-ST elevation acute coronary syndrome event o Outline Angiographic Inclusion Criterion (after angiography): Presence of significant coronary disease defined as: Any stenosis >30% reduction in luminal diameter, by visual estimate, in at least one vessel (main or branch) of sufficient calibre to permit the potential performance of PCI - approximately 2.25 mm diameter. Key Exclusion Criteria Screening phase exclusion criteria: ≤ 18 years of age Previous enrolment in this trial Currently enrolled into another study unless co-enrolment approved by Chief Investigator (CI) and the clinical trials unit (CTU) Inability to provide informed consent Residence outside the United Kingdom (UK) or other issues limiting the ability to secure clinical follow-up data to one year Non-cardiac pathology that may limit survival in the next year Clear contraindication to potential future management with CABG or PCI (patients should be a potential candidate for medical therapy or revascularisation with either PCI or surgery) Heart valve disease of sufficient import to consider valve replacement or other intervention as part of an index management strategy Hypertrophic cardiomyopathy Previous coronary artery surgery of any type Known chronic renal impairment with a current estimated glomerular filtration rate (eGFR) of < 45 Anaemia with a current measured haemoglobin of < 100 Angiography performed in the context of an ST elevation myocardial infarction event Any patient who at the time of planned angiography manifests haemodynamic instability, or recurrent sustained ventricular arrhythmia, or Mobitz type II or complete heart block Any patient who at the time of planned angiography manifests unstable chest pain symptoms at rest or has required the continuing use of intravenous nitrates or regular opioid analgesia to control symptoms Continuing use of intravenous glycoprotein 2b/3a (GP2b3a) agents before entry to the catheterisation laboratory Known intolerance, hypersensitivity or contraindication to adenosine - including significant reversible airways disease Additional investigations planned (or deemed likely to be required) for the assessment of myocardial ischaemia or viability. Examples of proposed tests that would constitute an exclusion criterion would include, but are not limited to, exercise tolerance testing, stress echocardiography, cardiac MRI viability or perfusion scanning or nuclear myocardial perfusion scanning. Active bleeding at the time of planned index angiography Pregnant women Angiographic phase exclusion criteria: Single vessel occlusive coronary disease (TIMI flow <3) as sole disease Patient not suitable for the immediate performance of a pressure wire assessment of all major vessels for any reason, for example: Patient discomfort Change in the clinical condition or complication of angiography requiring termination of the procedure or immediate intervention Significant use of radiographic contrast or X-Ray exposure during the initial angiography Inadequate angiographic images or failure to intubate any of the coronary vessels Aorto-ostial disease that would preclude accurate assessment of FFR Insufficient laboratory time Uncertain availability of key clinical and trial staff PW use in coronaries declared unsafe (e.g. tight or long disease) PW use in coronaries declared unsuitable (e.g. distal disease or complete cross-filling)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicholas Curzen, BM PhD FRCP
Organizational Affiliation
University Hospital Southampton NHS Foundation Trust
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rod H Stables, MA, DM, BM BCH, FRCP
Organizational Affiliation
Liverpool Heart and Chest Hospital NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Bournemouth Hospital - The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
City
Bournemouth
State/Province
Dorset
ZIP/Postal Code
BH7 7DW
Country
United Kingdom
Facility Name
Brighton and Sussex University Hospitals NHS Trust
City
Brighton
State/Province
East Sussex
ZIP/Postal Code
BN2 5BE
Country
United Kingdom
Facility Name
Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust
City
Portsmouth
State/Province
Hampshire
ZIP/Postal Code
PO6 3LY
Country
United Kingdom
Facility Name
Southampton General Hospital - University Hospitals Southampton NHS Foundation Trust
City
Southampton
State/Province
Hampshire
ZIP/Postal Code
SO16 6YD
Country
United Kingdom
Facility Name
Royal Blackburn Teaching Hospital - East Lancashire Hospitals NHS Trust
City
Blackburn
State/Province
Lancashire
ZIP/Postal Code
BB2 3HH
Country
United Kingdom
Facility Name
Liverpool Heart and Chest Hospital NHS Foundation Trust
City
Liverpool
State/Province
Merseyside
ZIP/Postal Code
L14 3PE
Country
United Kingdom
Facility Name
Freeman Hospital - Newcastle Hospitals
City
Newcastle upon Tyne
State/Province
Northumberland
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Facility Name
King's Mill Hospital - Sherwood Forest Hospitals NHS Foundation Trust
City
Mansfield
State/Province
Nottinghamshire
ZIP/Postal Code
NG17 4JL
Country
United Kingdom
Facility Name
City Hospital - Nottingham University Hospitals NHS Trust
City
Nottingham
State/Province
Nottinghamshire
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Facility Name
Golden Jubilee National Hospital
City
Glasgow
State/Province
Scotland
ZIP/Postal Code
G81 4DY
Country
United Kingdom
Facility Name
Northern General Hospital - Sheffield Teaching Hospitals
City
Sheffield
State/Province
South Yorkshire
ZIP/Postal Code
S5 7AU
Country
United Kingdom
Facility Name
Royal Stoke University Hospital - University Hospitals of North Midlands
City
Stoke-on-Trent
State/Province
Staffordshire
ZIP/Postal Code
ST4 6QG
Country
United Kingdom
Facility Name
Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust
City
Birmingham
State/Province
West Midlands
ZIP/Postal Code
B15 2TH
Country
United Kingdom
Facility Name
Pinderfields Hospital - The Mid Yorkshire Hospitals NHS Trust
City
Wakefield
State/Province
West Yorkshire
ZIP/Postal Code
WF1 4DG
Country
United Kingdom
Facility Name
Castle Hill Hospital - Hull and East Yorkshire Hospitals NHS Trust
City
Hull
State/Province
Yorkshire
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Facility Name
Leeds General Infirmary - Leeds Teaching Hospitals NHS Trust
City
Leeds
State/Province
Yorkshire
ZIP/Postal Code
LS1 3EX
Country
United Kingdom
Facility Name
Bristol Heart Institute - University Hospitals Bristol NHS Foundation Trust
City
Bristol
ZIP/Postal Code
BS2 8HW
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
1253383
Citation
Zir LM, Miller SW, Dinsmore RE, Gilbert JP, Harthorne JW. Interobserver variability in coronary angiography. Circulation. 1976 Apr;53(4):627-32. doi: 10.1161/01.cir.53.4.627.
Results Reference
background
PubMed Identifier
6700670
Citation
White CW, Wright CB, Doty DB, Hiratza LF, Eastham CL, Harrison DG, Marcus ML. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? N Engl J Med. 1984 Mar 29;310(13):819-24. doi: 10.1056/NEJM198403293101304.
Results Reference
background
PubMed Identifier
8124786
Citation
De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol A, Paulus WJ, Heyndrickx GR, Wijns W. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation. 1994 Mar;89(3):1013-22. doi: 10.1161/01.cir.89.3.1013.
Results Reference
background
PubMed Identifier
8637515
Citation
Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996 Jun 27;334(26):1703-8. doi: 10.1056/NEJM199606273342604.
Results Reference
background
PubMed Identifier
16053955
Citation
Berger A, Botman KJ, MacCarthy PA, Wijns W, Bartunek J, Heyndrickx GR, Pijls NH, De Bruyne B. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. J Am Coll Cardiol. 2005 Aug 2;46(3):438-42. doi: 10.1016/j.jacc.2005.04.041.
Results Reference
background
PubMed Identifier
19144937
Citation
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611.
Results Reference
background
PubMed Identifier
17531660
Citation
Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, Bar F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007 May 29;49(21):2105-11. doi: 10.1016/j.jacc.2007.01.087. Epub 2007 May 17.
Results Reference
background
PubMed Identifier
20537493
Citation
Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van't Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010 Jul 13;56(3):177-84. doi: 10.1016/j.jacc.2010.04.012. Epub 2010 May 28.
Results Reference
background
PubMed Identifier
22924638
Citation
De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Mobius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrom T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Juni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012 Sep 13;367(11):991-1001. doi: 10.1056/NEJMoa1205361. Epub 2012 Aug 27. Erratum In: N Engl J Med. 2012 Nov;367(18):1768. Mobius-Winckler, Sven [corrected to Mobius-Winkler, Sven].
Results Reference
background
PubMed Identifier
23984928
Citation
Longman K, Curzen N. Should ischemia be the main target in selecting a percutaneous coronary intervention strategy? Expert Rev Cardiovasc Ther. 2013 Aug;11(8):1051-9. doi: 10.1586/14779072.2013.814856.
Results Reference
background
PubMed Identifier
24644308
Citation
Toth G, Hamilos M, Pyxaras S, Mangiacapra F, Nelis O, De Vroey F, Di Serafino L, Muller O, Van Mieghem C, Wyffels E, Heyndrickx GR, Bartunek J, Vanderheyden M, Barbato E, Wijns W, De Bruyne B. Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. Eur Heart J. 2014 Oct 21;35(40):2831-8. doi: 10.1093/eurheartj/ehu094. Epub 2014 Mar 18.
Results Reference
background
PubMed Identifier
24642999
Citation
Curzen N, Rana O, Nicholas Z, Golledge P, Zaman A, Oldroyd K, Hanratty C, Banning A, Wheatcroft S, Hobson A, Chitkara K, Hildick-Smith D, McKenzie D, Calver A, Dimitrov BD, Corbett S. Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain?: the RIPCORD study. Circ Cardiovasc Interv. 2014 Apr;7(2):248-55. doi: 10.1161/CIRCINTERVENTIONS.113.000978. Epub 2014 Mar 18.
Results Reference
background
PubMed Identifier
25689940
Citation
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Glob Heart. 2012 Dec;7(4):275-95. doi: 10.1016/j.gheart.2012.08.001. Epub 2012 Sep 26. No abstract available.
Results Reference
background
PubMed Identifier
15201249
Citation
Weintraub WS, Mahoney EM, Zhang Z, Chu H, Hutton J, Buxton M, Booth J, Nugara F, Stables RH, Dooley P, Collinson J, Stuteville M, Delahunty N, Wright A, Flather MD, De Cock E. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart. 2004 Jul;90(7):782-8. doi: 10.1136/hrt.2003.015057.
Results Reference
background
PubMed Identifier
12975252
Citation
Zhang Z, Mahoney EM, Stables RH, Booth J, Nugara F, Spertus JA, Weintraub WS. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. Circulation. 2003 Oct 7;108(14):1694-700. doi: 10.1161/01.CIR.0000087600.83707.FD. Epub 2003 Sep 15.
Results Reference
background
PubMed Identifier
12383664
Citation
SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet. 2002 Sep 28;360(9338):965-70. doi: 10.1016/S0140-6736(02)11078-6.
Results Reference
background
PubMed Identifier
24255062
Citation
Van Belle E, Rioufol G, Pouillot C, Cuisset T, Bougrini K, Teiger E, Champagne S, Belle L, Barreau D, Hanssen M, Besnard C, Dauphin R, Dallongeville J, El Hahi Y, Sideris G, Bretelle C, Lhoest N, Barnay P, Leborgne L, Dupouy P; Investigators of the Registre Francais de la FFR-R3F. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry. Circulation. 2014 Jan 14;129(2):173-85. doi: 10.1161/CIRCULATIONAHA.113.006646. Epub 2013 Nov 19.
Results Reference
background
Citation
Henderson R, Lee L. The epidemiology and pathophysiology of coronary artery disease. Chapter 1 in The Oxford Textbook of Interventional Cardiology. Eds: Redwood, Curzen, Thomas. Oxford University Press 2010.
Results Reference
background
Citation
Muller O, De Bruyne B. Coronary physiology in clinical practice. Chapter 9 in in The Oxford Book of Interventional Cardiology. Eds: Redwood, Curzen, Thomas. Oxford University Press 2010.
Results Reference
background
Citation
Chest Pain of Recent Onset. NICE Guidance CG95, 2010. https://www.nice.org.uk/guidance/CG95
Results Reference
background
PubMed Identifier
29449442
Citation
Elguindy M, Stables R, Nicholas Z, Kemp I, Curzen N. Design and Rationale of the RIPCORD 2 Trial (Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?): A Randomized Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease. Circ Cardiovasc Qual Outcomes. 2018 Feb;11(2):e004191. doi: 10.1161/CIRCOUTCOMES.117.004191.
Results Reference
derived

Learn more about this trial

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?

We'll reach out to this number within 24 hrs